White Paper

COVID-19 Vaccine Clinical Trials In Children: Challenges On The Horizon

By Renee Simar, Ph.D., Elligo Pediatric Advisory, Board Chair

Pediatrics iStock-1223445550

Vaccine clinical trials against COVID-19 in adults are leading the effort before studies begin in children. Although early reports show COVID-19 symptoms tend to be milder in children, some develop severe manifestations of the disease. With an even larger gap in symptomology between adults and children, adult trials will not be easily adaptable to children.

Despite decades of progress in pediatric product development, pediatric clinical research remains challenging. A comment from FDA’s Dr. Dianne Murphy in 1999 highlights a relevant keystone during the rapid pace of this pandemic, “We have a very high bar to pass if we are going to enroll children in clinical trials.”1 Adapting the accelerated activities in the adult vaccine programs to children will be inherently difficult as clinical trials will be needed to establish safety and efficacy. However, this goal is achievable with strategic, early planning to ensure ethical trial conduct.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: